In Brief: Bristol-Myers Squibb Serzone
Bristol-Myers Squibb Serzone: Company commences $20 mil., multi-center, chronic depression treatment study involving 660 patients comparing the safety and efficacy of nefazodone HC1 with cognitive behavior therapy. "Serzone and CBT-CD will be evaluated separately and in combination during acute and continuation treatment of patients with chronic major depression and double depression," Bristol says. The study will also include a one-year maintenance treatment phase comparing Serzone to placebo in the maintenance of clinical response...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth